Document is current
Any future updates will be listed below
-
Authors
Sebera, Fidele
Dedeken, Peter https://orcid.org/0000-0001-8493-6276
Kayirangwa, Jeannine
Umwiringirwa, Josiane
Kajeneza, Delphine
dos Reis, Nicole Alves
Leers, Tim
Teuwen, Dirk E.
Boon, Paul A. J. M.
-
Funding
Funding for this research was provided by:
UCB
- License Information
-
More Information
Article History
Received: 9 September 2020
Accepted: 5 January 2022
First Online: 21 January 2022
Declarations
:
: The survey study was approved by the College of Medicine and Health Sciences—Institutional Review Board (Kigali, Rwanda) [461/CMBS-IRB/2016], the Institutional Review Boards of the CARAES Neuro-Psychiatric Hospital of Ndera (Kigali, Rwanda) and the Ruhengeri Referral Hospital (Musanze, Rwanda).
: Consent for publication was obtained from FS, DET, NAdR, JK, JU, DK, PD, TL, and PAJMB.
: DET is an employee of UCB Pharma, now retired. PD has received consultancy fees from UCB Pharma, Merck, and Novartis Pharma. PAMJB has received speaker and consultancy fees from UCB Pharma and various other pharmaceutical companies, and research grants through his institution. DK received an unrestricted grant from the UCB Corporate Societal Responsibility department to complete the Master of Neurology training at the University of Cheikh Anta Diop (Dakar, Senegal). TL received compensation for performing the statistical analysis and creating visualizations. Other authors have no competing interests.
